Literature DB >> 18559489

Emerging roles of DMP1 in lung cancer.

Kazushi Inoue1, Takayuki Sugiyama, Pankaj Taneja, Rachel L Morgan, Donna P Frazier.   

Abstract

The Ras-activated transcription factor DMP1 can stimulate Arf transcription to promote p53-dependent cell arrest. One recent study deepens the pathophysiologic significance of this pathway in cancer, first, by identifying DMP1 losses in human lung cancers that lack ARF/p53 mutations, and second, by demonstrating that Dmp1 deletions in the mouse are sufficient to promote K-ras-induced lung tumorigenesis via mechanisms consistent with a disruption of Arf/p53 suppressor function. These findings prompt further investigations of the prognostic value of DMP1 alterations in human cancers and the oncogenic events that can cooperate with DMP1 inactivation to drive tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18559489      PMCID: PMC3723119          DOI: 10.1158/0008-5472.CAN-07-6791

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

Review 1.  Haplo-insufficiency? Let me count the ways.

Authors:  K C Quon; A Berns
Journal:  Genes Dev       Date:  2001-11-15       Impact factor: 11.361

Review 2.  Multidisciplinary management of lung cancer.

Authors:  Alexander Spira; David S Ettinger
Journal:  N Engl J Med       Date:  2004-01-22       Impact factor: 91.245

3.  Somatic activation of the K-ras oncogene causes early onset lung cancer in mice.

Authors:  L Johnson; K Mercer; D Greenbaum; R T Bronson; D Crowley; D A Tuveson; T Jacks
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

4.  Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas.

Authors:  K Inoue; F Zindy; D H Randle; J E Rehg; C J Sherr
Journal:  Genes Dev       Date:  2001-11-15       Impact factor: 11.361

5.  Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.

Authors:  C M Eischen; J D Weber; M F Roussel; C J Sherr; J L Cleveland
Journal:  Genes Dev       Date:  1999-10-15       Impact factor: 11.361

6.  Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis.

Authors:  K Inoue; R Wen; J E Rehg; M Adachi; J L Cleveland; M F Roussel; C J Sherr
Journal:  Genes Dev       Date:  2000-07-15       Impact factor: 11.361

Review 7.  Tumor suppression by Ink4a-Arf: progress and puzzles.

Authors:  Scott W Lowe; Charles J Sherr
Journal:  Curr Opin Genet Dev       Date:  2003-02       Impact factor: 5.578

8.  Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patterns.

Authors:  Mario P Tschan; Kimberlee M Fischer; Vivian S Fung; Farzaneh Pirnia; Markus M Borner; Martin F Fey; Andreas Tobler; Bruce E Torbett
Journal:  J Biol Chem       Date:  2003-08-12       Impact factor: 5.157

9.  Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer.

Authors:  I Bièche; M H Champème; F Matifas; K Hacène; R Callahan; R Lidereau
Journal:  Lancet       Date:  1992-01-18       Impact factor: 79.321

10.  Repression of Dmp1 and Arf transcription by anthracyclins: critical roles of the NF-kappaB subunit p65.

Authors:  P Taneja; A Mallakin; L A Matise; D P Frazier; M Choudhary; K Inoue
Journal:  Oncogene       Date:  2007-06-04       Impact factor: 9.867

View more
  13 in total

1.  Aberrant expression of cyclin D1 in cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Sign Transduct Insights       Date:  2015-09-20

2.  Regulation of murine hematopoietic stem cell quiescence by Dmtf1.

Authors:  Michihiro Kobayashi; Edward F Srour
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

Review 3.  Transcription factors that interact with p53 and Mdm2.

Authors:  Kazushi Inoue; Elizabeth A Fry; Donna P Frazier
Journal:  Int J Cancer       Date:  2015-07-14       Impact factor: 7.396

4.  Clinical applications of mouse models for breast cancer engaging HER2/neu.

Authors:  Elizabeth A Fry; Pankaj Taneja; Kazushi Inoue
Journal:  Integr Cancer Sci Ther       Date:  2016-10-28

5.  Haploinsufficient tumor suppressor genes.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Adv Med Biol       Date:  2017 1st Quarter

6.  Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Takayuki Sugiyama; Robert D Kendig; Donna P Frazier; Mark C Willingham; Kazushi Inoue
Journal:  Cancer Res       Date:  2010-11-09       Impact factor: 12.701

7.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

8.  Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer.

Authors:  D Maglic; S Zhu; E A Fry; P Taneja; F Kai; R D Kendig; T Sugiyama; L D Miller; M C Willingham; K Inoue
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

Review 9.  Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Int J Cancer       Date:  2016-02-08       Impact factor: 7.396

10.  Whole Exome Sequencing of Highly Aggregated Lung Cancer Families Reveals Linked Loci for Increased Cancer Risk on Chromosomes 12q, 7p, and 4q.

Authors:  Anthony M Musolf; Bilal A Moiz; Haiming Sun; Claudio W Pikielny; Yohan Bossé; Diptasri Mandal; Mariza de Andrade; Colette Gaba; Ping Yang; Yafang Li; Ming You; Ramaswamy Govindan; Richard K Wilson; Elena Y Kupert; Marshall W Anderson; Ann G Schwartz; Susan M Pinney; Christopher I Amos; Joan E Bailey-Wilson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-12-11       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.